Botulinum A toxin for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms

Current Urology Reports

Volumn 7, Issue 4, 2006, Pages 266-271

  Thomas, Catherine A ^b   Chuang, Yao Chi ^b   Giannantoni, Antonella ^b   Chancellor, Michael B ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CALCITONIN GENE RELATED PEPTIDE; GLUTAMIC ACID; NEUROPEPTIDE; NORADRENALIN; SUBSTANCE P;

ARTHRALGIA; AUTONOMIC NERVOUS SYSTEM; CHOLINERGIC SYNAPSE; CLOSTRIDIUM BOTULINUM; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MIGRAINE; MYOFASCIAL PAIN; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; PROSTATE HYPERTROPHY; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; RISK FACTOR; SENSORY NERVE; SYMPTOMATOLOGY; TRANSURETHRAL RESECTION; URINARY TRACT DISEASE; DRUG EFFECT; MALE; NERVE CELL; PROSTATE TUMOR;

BOTULINUM TOXIN TYPE A; HUMANS; MALE; NEURONS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 33748744631     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-996-0005-1     Document Type: Review

References (35)

1. Jacobsen SJ, Girman CJ, Guess HA, et al.: New diagnostic and treatment guidelines for benign prostatic hyperplasia: potential impact in the United States. Arch Intern Med 1995, 155:477-481.
2. Van Ermengem EP: Uber einen neuen anaroben Bacillus und seine Beziehung zum Botulismus. Infektionskrankh 1897, 26:1-56
3. (English translation: Classics in infectious diseases: a new anaerobic bacillus and its relation to botulism. Rev Infect Dis 1979, 4:701-719).
4. DasGupta BR: Structures of botulinum neurotoxin, its functional domains, and perspectives on the crystalline type A toxin. In Therapy with Botulinum Toxin. Edited by Jankovic J., Hallen M. New York: Marcel Dekker; 1994:15-39.
5. Aoki KR, Guyer B: Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001, 8(suppl 5):21-29.
6. Scott AB, Suzuki D: Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 1988, 3:333-335.
7. Aoki KR: Preclinical update on Botox (botulinum toxin type A) purified neurotoxin complex relative to other Botulinum neurotoxin preparations. Eur J Neurol 1999, 6(suppl 4):S3-S10.
8. Simpson LL: Molecular pharmacology on Botulinum toxin and tetanus toxin. Annu Rev Pharmacol Toxicol 1986, 26:427-453.
9. Santos JI, Swensen P, Glasgow LA: Potentiation of clostridium botulinum toxin aminoglycoside antibiotics: clinical and laboratory observations. Pediatrics 1981, 68:50-54.
10. dePaiva A, Meunier FA, Folgo A, et al.: Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999, 96:3200-3205.
11. Haferkamp A, Schurch B, Reitz A, et al.: Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder. Eur Neurol 2004, 46:784-791.
12. Mackenzie I, Burnstock G, Dolly JO: The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience 1982, 7:997-1006.
13. Dressler D, Saberi FA, Barbosa ER: Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr 2005, 63:180-185.
14. Smith CP, Franks ME, McNeil BK, et al.: Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 2003, 169:1896-1900.
15. Cui M, Khanijou S, Rubino J, et al.: Subcutaneous administration of botulinum toxin type A reduces formalin-induced pain. Pain 2004, 107:125-133.
16. Chuang YC, Yoshimura N, Huang CC, et al.: Intravesical botulinum toxin A administration produces analgesia against acetic acid-induced bladder pain responses in rats. J Urol 2004, 172:1529-1532.
17. Welch MJ, Purkiss JR, Foster KA: Sensitivity of embryonic rat dorsal root ganglia neurons to clostridium Botulinum neurotoxins. Toxicon 2000, 38:245-258.
18. Purkiss J, Wekch M, Doward S, et al.: Capsaicin-stimulated release of substance P release from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 2000, 59:1403-1406.
19. Ishikawa H, Mitsui Y, Yoshitomi T, et al.: Presynaptic effects of botulinum toxin A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and iris dilator muscles. Jpn J Ophthalmol 2000, 44:106-109.
20. Durham PL, Cady R: Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004, 44:35-43.
21. Pennefather JN, Lau WA, Mitchelson F, et al.: The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmacological and histological studies. J Auton Pharmacol 2000, 20:193-206.
22. Lepor H: The pathophysiology of lower urinary tract symptoms in the ageing male population. Br J Urol 1998, 81:29-33.
23. Maria G, Brisinda G, Civello IM, et al.: Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003, 62:259-265. The authors, researchers from the departments of Surgery and Neurology, Catholic School of Medicine, initiated the therapeutic role of botulinum toxin injection in men with BPH. They found that 86.6% in the treated group versus 20% in the control group had symptomatic improvement at the 2-month follow-up. Patient's treated with botulinum toxin had a significant improvement in maximum flow rates by 52%, postvoid residual by 83%, and AUA symptom score by 65%. The most fascinating aspect of this study was the reduction of prostate volumes by 68% and the decrease in PSA levels by 51%. The results showed botulinum toxin to be safe, effective treatment option for patients who suffer from BPH.
24. Kuo HC: Prostate Botulinum toxin A injection: an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005, 65:670-674. The author, from the Department of Urology, Buddhist Tzu Chi General Hospital, Hualien Taiwan, studied the clinical effectiveness of prostate injection of botulinum A toxin in the treatment of patients with BPH and bladder outlet obstruction who were poor surgical candidates. The author found the following improvements with patients in their 3-month follow-up: spontaneous voiding (100%), voiding pressure (16.8%), postvoid residual volume (77.8%), maximal flow rate (30.3), and prostate volumes (29.9%) after treatment. The results of the effects of botulinum A toxin are very exciting and encouraging for patients who have failed or are poor surgical candidates for BPH and bladder outlet obstruction.
25. Chuang YC, Chiang PH, Huang CC, et al.: Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 2005, 66:775-779.
26. Park DS, Cho TW, Lee YK, et al.: Evaluation of short-term clinical effects and presumptive mechanism of Botulinum toxin type A as a treatment modality of benign prostatic hyperplasia [Abstract 487]. Abstract presented at the 35th Annual International Continence Society Meeting. Montreal: September 1-3, 2005.
27. Larson TR, Scottsdale AZ, Huidobro C, Acevedo C: Intraprostatic injection of botulinum toxin in the treatment of symptomatic LUTS, including sequential MRIS for accurate changes in size of the prostate. J Urol 2005, 173:376-377.
28. Guercini F, Giannantoni A, Bard RL, et al.: Intraprostatic botulinum toxin injection in patients with severe benign prostatic hyperplasia: a multicenter feasibility study. J Urol 2005, 173:376-377.
29. American Cancer Society Inc: 2005 Cancer facts and figures. http:/www.cancer.org
30. Parker SL, Tong T, Bolden S, et al.: Cancer Statistics, 1997. Cancer J Clin 1997, 47:5-27.
31. Nelson WG, De Marzo AM, De Weese TL, et al.: The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004, 172:S6-S11.
32. Walsh PC: Treatment of benign prostatic hyperplasia. N Engl J Med 1996, 335:557-563.
33. Chuang YC, Huang CC, Kang HY, et al.: Novel action of Botulinum toxin on the stromal and epithelial components of prostate gland. J Urol 2006, in press.
34. Dinis P, Charrua A, Avelino A, et al.: The distribution of sensory fibers immunoreactive for the TRPV1 (capsaicin) receptor in the human prostate. Eur Urol 2005, 48:162-167.
35. Plante MK, Folsom JB, Zvara P: Prostatic tissue ablation by injection: a literature review. J Urol 2004, 172:20-26.